1. Herrera FG, Prior JO. The role of PET/CT in cervical cancer. Front Oncol. 2013; 3:34.
Article
2. Nam H, Huh SJ, Ju SG, Park W, Lee JE, Choi JY, et al. 18F-fluorodeoxyglucose positron emisson tomography/computed tomography guided conformal brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2012; 84:e29–34.
Article
3. Oh D, Huh SJ, Park W, Ju SG, Nam H, Lee JE. Clinical outcomes in cervical cancer patients treated by FDG-PET/CT-based 3-dimensional planning for the first brachytherapy session. Medicine (Baltimore). 2016; 95:e3895.
Article
4. Engin G. Cervical cancer: MR imaging findings before, during, and after radiation therapy. Eur Radiol. 2006; 16:313–24.
Article
5. Yoon JW, Kim S, Kim SW, Kim YT, Kang WJ, Nam EJ. PET/CT response criteria (European Organization for Research and Treatment of Cancer) predict survival better than response evaluation criteria in solid tumors in locally advanced cervical cancer treated with chemoradiation. Clin Nucl Med. 2016; 41:677–82.
Article
6. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8:797–805.
Article
7. Kim N, Cho H, Yun M, Park KR, Lee CG. Prognostic values of mid-radiotherapy (18)F-FDG PET/CT in patients with esophageal cancer. Radiat Oncol. 2019; 14:27.
Article
8. Kim N, Kim JS, Geol Lee C. Predictive value of interim 18F-FDG-PET in patients with non-small cell lung cancer treated with definitive radiation therapy. PLoS One. 2020; 15:e0236350.
Article
9. Kim S, Oh S, Kim JS, Kim YK, Kim KH, Oh DH, et al. Prognostic value of FDG PET/CT during radiotherapy in head and neck cancer patients. Radiat Oncol J. 2018; 36:95–102.
Article
10. Haie-Meder C, Potter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005; 74:235–45.
Article
11. Kidd EA, Thomas M, Siegel BA, Dehdashti F, Grigsby PW. Changes in cervical cancer FDG uptake during chemoradiation and association with response. Int J Radiat Oncol Biol Phys. 2013; 85:116–22.
Article
12. Lin LL, Yang Z, Mutic S, Miller TR, Grigsby PW. FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. Int J Radiat Oncol Biol Phys. 2006; 65:177–81.
Article
13. Schwarz JK, Lin LL, Siegel BA, Miller TR, Grigsby PW. 18-F-Fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2008; 72:1502–7.
Article
14. Leseur J, Roman-Jimenez G, Devillers A, Ospina-Arango JD, Williaume D, Castelli J, et al. Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer. Radiother Oncol. 2016; 120:512–8.
Article
15. Oh D, Lee JE, Huh SJ, Park W, Nam H, Choi JY, et al. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2013; 87:549–54.
Article
16. Shen WC, Chen SW, Wu KC, Hsieh TC, Liang JA, Hung YC, et al. Prediction of local relapse and distant metastasis in patients with definitive chemoradiotherapy-treated cervical cancer by deep learning from [(18)F]-fluorodeoxyglucose positron emission tomography/computed tomography. Eur Radiol. 2019; 29:6741–9.
Article
17. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007; 110:1738–44.
Article
18. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol. 2010; 28:2108–13.
Article
19. Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutic S, Mutch DG, et al. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2010; 77:1085–91.
Article
20. Nam H, Park W, Huh SJ, Bae DS, Kim BG, Lee JH, et al. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol Oncol. 2007; 107:320–5.
Article
21. Fields EC, Weiss E. A practical review of magnetic resonance imaging for the evaluation and management of cervical cancer. Radiat Oncol. 2016; 11:15.
Article
22. Sun C, Tian X, Liu Z, Li W, Li P, Chen J, et al. Radiomic analysis for pretreatment prediction of response to neoadjuvant chemotherapy in locally advanced cervical cancer: a multicentre study. EBioMedicine. 2019; 46:160–9.
Article
23. Wormald BW, Doran SJ, Ind TE, D’Arcy J, Petts J, deSouza NM. Radiomic features of cervical cancer on T2-and diffusion-weighted MRI: prognostic value in low-volume tumors suitable for trachelectomy. Gynecol Oncol. 2020; 156:107–14.
Article
24. Lucia F, Visvikis D, Desseroit MC, Miranda O, Malhaire JP, Robin P, et al. Prediction of outcome using pretreatment (18)F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2018; 45:768–86.
Article
25. Lucia F, Visvikis D, Vallieres M, Desseroit MC, Miranda O, Robin P, et al. External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2019; 46:864–77.
Article
26. Lee JH, Lee SW, Kim JR, Kim YS, Yoon MS, Jeong S, et al. Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01. Gynecol Oncol. 2017; 147:577–84.
Article
27. Yang K, Park W, Huh SJ, Bae DS, Kim BG, Lee JW. Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer. Radiat Oncol J. 2017; 35:39–47.
Article
28. Noh JM, Park W, Kim YS, Kim JY, Kim HJ, Kim J, et al. Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROG 13-10). Gynecol Oncol. 2014; 132:618–23.
Article
29. Hodgson A, Park KJ. Cervical adenocarcinomas: a heterogeneous group of tumors with variable etiologies and clinical outcomes. Arch Pathol Lab Med. 2019; 143:34–46.
30. Hautzel H, Muller-Gartner HW. Early changes in fluorine-18-FDG uptake during radiotherapy. J Nucl Med. 1997; 38:1384–6.